1238.4000 -15.00 (-1.20%)
NSE Jan 02, 2026 09:38 AM
Volume: 132.9K
 

1238.40
-1.20%
Emkay
Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income.
Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.
More from Dr. Reddy's Laboratories Ltd.
Recommended